From the University of Alabama at Birmingham, Birmingham, Alabama; New England Research Institute, Watertown, Massachusetts; the University of California San Diego, San Diego, California; William Beaumont Hospital, Royal Oak, Michigan; the University of Maryland, Baltimore, Maryland; the University of Utah, Salt Lake City, Utah; the University of Texas Southwestern, Dallas, Texas; University Texas San Antonio, San Antonio, Texas; Magee Women's Hospital, Pittsburgh, Pennsylvania; Loyola University, Maywood, Illinois; and the National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland.
*For a list of other members of the Urinary Incontinence Treatment Network, see the Appendix online at https://links.lww.com/AOG/A229.
Supported by the National Institute of Diabetes and Digestive and Kidney Diseases U01 DK58231, U01 DK60379, U01 DK60380, U01 DK60401, U01 DK60397, U01DK58225, U01 DK60395, U01 DK58234, U01 DK60393, U01 DK58229 and 2K24-DK068389 to Dr. Richter.
Presented at the American Urogynecologic Society Meeting, September 29–October 2, 2010, Long Beach, California.
Corresponding author: Holly E. Richter, PhD, MD, 619 20th Street South, 176 F, Suite 10382, Birmingham, AL 35249; e-mail: [email protected].
Financial Disclosure Dr. Richter has been a consultant for Xanodyne Pharmaceuticals, Uromedica, and IDEO. She has received research grants and has been a consultant for Pfizer and Astellas. She has also received an education grant from Warner Chilcott. Dr. Lukacz has been a consultant and advisor to Pfizer and Watson. Dr. Fitzgerald has received a research grant from Astellas and speaker honorarium from Astellas, Pfizer, and Ferring. She also has been a consultant to Pfizer and Astellas. Dr. Rickey received research support from Pfizer and is a consultant for Ethicon. The other authors did not report any potential conflicts of interest.
